pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

7,982 catalysts · 4,876 phase readout · 2,346 8k filing · 286 earnings · 271 pdufa · 166 phase 2 completion · 71 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 0 catalysts2026-07-23: 0 catalysts2026-07-24: 8 catalysts2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type
  • phase readout4,876
  • 8k filing2,346
  • earnings286
  • pdufa271
  • phase 2 completion166
  • phase 1 completion71
  • phase 2 initiation54
  • phase 1 initiation39
  • phase 1 2 completion33
  • phase 0 trial completion23
  • therapy area
    • Oncology139
    • Infectious Disease41
    • Cardiology37
    • Immunology32
    • Dermatology27
    • Pulmonology19
    • Women's Health16
    • Ophthalmology15
    • Pain12

    Week of Apr 27, 2026

    50
    ›Apr 27, 2026phase 1 2 initiation89d agoThe National Institute of Diabetes and Digestive and Kidney Diseases — EBTATE (Phase I/II Trial Initiation)EBTATE

    Therapy area: Oncology. Indication: Thyroid Cancer

    full page →EBTATE →source: globaldata
    ›Apr 27, 2026phase 1 2 initiation89d agoNational Cancer Institute US — sacituzumab govitecan (Phase I/II Trial Initiation)sacituzumab govitecan

    Therapy area: Oncology. Indication: Neuroendocrine Cancer, Neuroendocrine Carcinoma, Small-Cell Lung Cancer

    full page →sacituzumab govitecan →source: globaldata
    ›Apr 27, 2026phase 2 completion89d agoSustained Therapeutics Inc — lidocaine SR (Phase II Trial Completion)LIDOCAINE

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →LIDOCAINE →source: globaldata
    ›Apr 27, 2026phase 2 completion89d agoSMBT Ayurved College and Hospital — ayurvedic medicine (Phase II Trial Completion)ayurvedic medicine

    Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye)

    full page →ayurvedic medicine →source: globaldata
    ›Apr 27, 2026phase 2 completion89d agoChacha Nehru Bal Chikitsalaya — bupivacaine (Phase II Trial Completion)bupivacaine

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →bupivacaine →source: globaldata
    ›Apr 27, 2026phase 2 completion89d agoEuropean and Developing Countries Clinical Trials Partnership — (diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine (Phase II Trial Completion)(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine

    Therapy area: Infectious Disease. Indication: Salmonella Infections

    full page →(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine →source: globaldata
    ›Apr 27, 2026phase 2 completion89d agoOrthomedico Inc — lactococcus lactis subsp. cremoris YRC3780 (Phase II Trial Completion)lactococcus lactis subsp. cremoris YRC3780

    Therapy area: Central Nervous System. Indication: Sleep Disorders

    full page →lactococcus lactis subsp. cremoris YRC3780 →source: globaldata
    ›Apr 27, 2026phase 2 completion89d agoPt.Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences Rohtak — nivolumab (Phase II Trial Completion)nivolumab

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Squamous Non-Small Cell Lung Cancer

    full page →nivolumab →source: globaldata
    ›Apr 27, 2026phase 2 completion89d agoChina Red Cross Foundation — sufentanil (Phase II Trial Completion)sufentanil

    Therapy area: Gastrointestinal, Genito Urinary System. Indication: Hernia, Urinary Retention

    full page →sufentanil →source: globaldata
    ›Apr 27, 2026phase 2 completion89d agoKonya City Hospital — fentanyl (Phase II Trial Completion)fentanyl ER

    Therapy area: Central Nervous System, Gastrointestinal. Indication: Post-Operative Pain, Postoperative Ileus

    full page →fentanyl ER →source: globaldata
    ›Apr 27, 2026phase 2 completion89d agoBC Children's Hospital Research Institute — dexamethasone (Phase II Trial Completion)dexamethasone

    Therapy area: Central Nervous System, Gastrointestinal. Indication: Appendicitis, Post-Operative Pain

    full page →dexamethasone →source: globaldata
    ›Apr 27, 2026phase 2 initiation89d agoTianjin Lisheng Pharmaceutical Co Ltd — aminophylline (Phase II Trial Initiation)aminophylline

    Therapy area: Cardiovascular, Respiratory. Indication: Asthma, Bronchitis, Emphysema, Pulmonary Edema

    full page →aminophylline →source: globaldata
    ›Apr 27, 2026phase 2 initiation89d agoShanghai Henlius Biotech Inc — HLX-35 (Phase II Trial Initiation)HLX-35

    Therapy area: Oncology. Indication: Solid Tumor, Squamous Non-Small Cell Lung Cancer

    full page →HLX-35 →source: globaldata
    ›Apr 27, 2026phase 2 initiation89d agoAnkara Etlik City Hospital — bupivacaine (Phase II Trial Initiation)bupivacaine

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →bupivacaine →source: globaldata
    ›Apr 27, 2026phase 2 initiation89d agoBrainBees Solutions Ltd — Babyhug pro soothing relief diaper rash cream (Phase II Trial Initiation)Babyhug pro soothing relief diaper rash cream

    Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders

    full page →Babyhug pro soothing relief diaper rash cream →source: globaldata
    ›Apr 27, 2026phase 2 initiation89d agoMahatma Gandhi Medical College and Hospital — rosuvastatin (Phase II Trial Initiation)rosuvastatin

    Therapy area: Cardiovascular. Indication: Acute Coronary Syndrome, Myocardial Infarction

    full page →rosuvastatin →source: globaldata
    ›Apr 27, 2026phase 2 initiation89d agoJiangsu Hengrui Pharmaceuticals Co Ltd — HRS-3738 (Phase II Trial Initiation)HRS-3738

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma

    full page →HRS-3738 →source: globaldata
    ›Apr 27, 2026phase 2 initiation89d agoYichun Maternal and Child health Care Hospital — sufentanil (Phase II Trial Initiation)sufentanil

    Therapy area: Central Nervous System, Women's Health. Indication: Labor And Delivery, Pain

    full page →sufentanil →source: globaldata
    ›Apr 27, 2026phase 2 initiation89d agoTilman SA — turmeric rhizome dry extract (Curcuma longa) (Phase II Trial Initiation)turmeric rhizome dry extract (Curcuma longa)

    Therapy area: Undisclosed. Indication: Unspecified

    full page →turmeric rhizome dry extract (Curcuma longa) →source: globaldata
    ›Apr 27, 2026phase 2 initiation89d agoWeifang Yidu Central Hospital — liposome bupivacaine (Phase II Trial Initiation)liposome bupivacaine

    Therapy area: Oncology. Indication: Lung Cancer

    full page →liposome bupivacaine →source: globaldata
    ›Apr 27, 2026phase 2 initiation89d agoNational Cancer Institute US — busulfan (Phase II Trial Initiation)busulfan

    Therapy area: Oncology. Indication: Blood Cancer, Hematological Tumor, Leukemia, Lymphoma

    full page →busulfan →source: globaldata
    ›Apr 27, 2026phase 2 initiation89d agoCentral South University Xiangya Hospital 3 — HRS-2129 (Phase II Trial Initiation)HRS-2129

    Therapy area: Central Nervous System. Indication: Pain

    full page →HRS-2129 →source: globaldata
    ›Apr 27, 2026phase 2 initiation89d agoCarlo Bo University of Urbino — Colipral (Phase II Trial Initiation)Colipral

    Therapy area: Gastrointestinal. Indication: Unspecified Gastrointestinal Disorders

    full page →Colipral →source: globaldata
    ›Apr 27, 2026phase 2 initiation89d agoShree Saptashrungi Ayurved Mahavidyalay & Hospital — ayurvedic medicine (Phase II Trial Initiation)ayurvedic medicine

    Therapy area: Other Diseases. Indication: Injury

    full page →ayurvedic medicine →source: globaldata
    ›Apr 27, 2026phase 2 initiation89d agoThe National Institute of Diabetes and Digestive and Kidney Diseases — thioctic acid (Phase II Trial Initiation)thioctic acid

    Therapy area: Metabolic Disorders. Indication: Insulin Resistance, Obesity

    full page →thioctic acid →source: globaldata
    ›Apr 27, 2026phase 2 initiation89d agoNational Institute of Neurological Disorders and Stroke — brincidofovir (Phase II Trial Initiation)brincidofovir

    Therapy area: Infectious Disease. Indication: Progressive Multifocal Leukoencephalopathy

    full page →brincidofovir →source: globaldata
    ›Apr 27, 2026phase 2 initiation89d agoJiangsu Hengrui Pharmaceuticals Co Ltd — fruquintinib (Phase II Trial Initiation)fruquintinib

    Therapy area: Oncology. Indication: Colorectal Cancer

    full page →fruquintinib →source: globaldata
    ›Apr 27, 2026phase 2 initiation89d agoNational Cancer Institute US — cyclophosphamide (Phase II Trial Initiation)cyclophosphamide

    Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

    full page →cyclophosphamide →source: globaldata
    ›Apr 27, 2026phase 2 initiation89d agoChongqing Cancer Hospital — ondansetron (Phase II Trial Initiation)ondansetron ODT

    Therapy area: Oncology. Indication: Ovarian Cancer

    full page →ondansetron ODT →source: globaldata
    ›Apr 27, 2026phase 2 initiation89d agoAlfred Health Victoria — amiodarone (Phase II Trial Initiation)amiodarone

    Therapy area: Cardiovascular. Indication: Atrial Fibrillation, Congestive Heart Failure (Heart Failure)

    full page →amiodarone →source: globaldata
    ›Apr 27, 2026phase 2 3 completion89d agoAnthem Biosciences Ltd — berubicin hydrochloride (Phase II/III Trial Completion)berubicin hydrochloride

    Therapy area: Oncology. Indication: Glioblastoma Multiforme (GBM), Recurrent Glioblastoma Multiforme (GBM)

    full page →berubicin hydrochloride →source: globaldata
    ›Apr 27, 2026phase 2 3 completion89d agoMaharashtra Institute of Dental Sciences & Research Dental College — denosumab (Phase II/III Trial Completion)denosumab

    Therapy area: Mouth and Dental Disorders. Indication: Unspecified Mouth and Dental Disorders

    full page →denosumab →source: globaldata
    ›Apr 27, 2026phase 2 3 initiation89d agoKLES Dr Prabhakar Kore Hospital & Medical Research Centre — esmolol (Phase II/III Trial Initiation)esmolol

    Therapy area: Dermatology. Indication: Diabetic Foot Ulcers

    full page →esmolol →source: globaldata
    ›Apr 27, 2026phase 2 3 initiation89d agoSiddhakala Ayurvedik Medical College — ayurvedic medicine (Phase II/III Trial Initiation)ayurvedic medicine

    Therapy area: Gastrointestinal, Metabolic Disorders. Indication: Fatty Liver Disease, Hypercholesterolemia, Hypertriglyceridemia, Obesity

    full page →ayurvedic medicine →source: globaldata
    ›Apr 27, 2026phase 3 completion89d agoCellCarta Biosciences Inc — elranatamab (Phase III Trial Completion)elranatamab

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma, Relapsed Multiple Myeloma

    full page →elranatamab →source: globaldata
    ›Apr 27, 2026phase 3 completion89d agoSanofi — meningococcal [serotypes A, C, W-135, Y] vaccine (MenQuadfi) (Phase III Trial Completion)meningococcal [serotypes A, C, W-135, Y] vaccine (MenQuadfi)

    Therapy area: Infectious Disease. Indication: Neisseria meningitidis Infections

    full page →meningococcal [serotypes A, C, W-135, Y] vaccine (MenQuadfi) →source: globaldata
    ›Apr 27, 2026phase 3 initiation89d agoSun Pharmaceutical Industries Ltd — ruxolitinib (Phase III Trial Initiation)ruxolitinib

    Therapy area: Dermatology. Indication: Vitiligo

    full page →ruxolitinib →source: globaldata
    ›Apr 27, 2026phase 3 initiation89d agoZhuhai Qiwei Biotechnology Co Ltd — QA-102 (Phase III Trial Initiation)QA-102

    Therapy area: Ophthalmology. Indication: Choroidal Neovascularization, Dry (Atrophic) Macular Degeneration, Geographic Atrophy

    full page →QA-102 →source: globaldata
    ›Apr 27, 2026phase 3 initiation89d agoUniversity of Thessaly — abatacept (Phase III Trial Initiation)abatacept

    Therapy area: Immunology. Indication: Rheumatoid Arthritis

    full page →abatacept →source: globaldata
    ›Apr 27, 2026phase 3 initiation89d agoSiriraj Hospital — tranexamic acid (Phase III Trial Initiation)tranexamic acid

    Therapy area: Cardiovascular, Dermatology. Indication: Melasma (Chlosma), Venous Thromboembolism

    full page →tranexamic acid →source: globaldata
    ›Apr 27, 2026phase 3 initiation89d agoGan & Lee Pharmaceuticals Co Ltd — bofanglutide (Phase III Trial Initiation)bofanglutide

    Therapy area: Respiratory. Indication: Obstructive Sleep Apnea

    full page →bofanglutide →source: globaldata
    ›Apr 27, 2026phase 3 initiation89d agoDr. D. Y. Patil Dental College & Hospital — platelet rich fibrin (Phase III Trial Initiation)platelet rich fibrin

    Therapy area: Genito Urinary System, Non Malignant Disorders. Indication: Burning Sensation, Oral Submucosal Fibrosis

    full page →platelet rich fibrin →source: globaldata
    ›Apr 27, 2026phase iv trial initiation89d agoAll India Institute of Medical Sciences Patna — typhoid Vi polysaccharide vaccine (Phase IV Trial Initiation)typhoid Vi polysaccharide vaccine

    Therapy area: Infectious Disease. Indication: Typhoid Fever

    full page →typhoid Vi polysaccharide vaccine →source: globaldata
    ›Apr 27, 2026phase iv trial initiation89d agoJawaharlal Nehru Medical College — dexamethasone (Phase IV Trial Initiation)dexamethasone

    Therapy area: Central Nervous System, Genito Urinary System. Indication: Post-Operative Pain, Renal Stones/Calculi

    full page →dexamethasone →source: globaldata
    ›Apr 27, 2026phase iv trial initiation89d agoD Y Patil University School of Medicine — palonosetron (Phase IV Trial Initiation)palonosetron

    Therapy area: Gastrointestinal. Indication: Post Operative Nausea And Vomiting

    full page →palonosetron →source: globaldata
    ›Apr 27, 2026phase iv trial initiation89d agoAjou University Hospital — (acetaminophen + ibuprofen sodium) (Phase IV Trial Initiation)(acetaminophen + ibuprofen sodium)

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →(acetaminophen + ibuprofen sodium) →source: globaldata
    ›Apr 27, 2026phase iv trial initiation89d agoPostgraduate Institute of Medical Education and Research — esomeprazole (Phase IV Trial Initiation)esomeprazole DR-ODT

    Therapy area: Gastrointestinal. Indication: Pancreatitis

    full page →esomeprazole DR-ODT →source: globaldata
    ›Apr 27, 2026phase iv trial initiation89d agoKS Hegde Medical Academy — hyperbaric bupivacaine (Phase IV Trial Initiation)hyperbaric bupivacaine

    Therapy area: Central Nervous System. Indication: Back Pain

    full page →hyperbaric bupivacaine →source: globaldata
    ›Apr 27, 20268k filing89d ago$ADGM — Adagio Medical Holdings, Inc. (ADGM) — 8-K filing

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 27, 20268k filing89d ago$OGN — Organon & Co. (OGN) — 8-K filing

    Items: 1.01, 5.02, 7.01, 9.01

    full page →edgar 8k ↗
    ← prev
    page 3 of 160
    next →
    $SNY43.36-0.98%